Bausch & Lomb completes purchase of Eyeonics

ROCHESTER, N.Y. Bausch & Lomb has completed its acquisition of the ophthalmic medical device company Eyeonics.

Eyeonics now will now act as a wholly owned subsidiary of Bausch & Lomb. Its crystalens intraocular lens, the first and only Food and Drug Administration-approved accommodating IOL for the treatment of cataracts, joins Bausch & Lomb’s portfolio of innovative ophthalmic surgical products for the cataract, vitreoretinal and refractive markets.

Terms of the deal were not disclosed.